A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
← catalyst calendarNCT07061288 · readout in 306 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
116estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-03 | actual | When the study began enrolling |
| Primary completion | 2027-06-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Intervention
- Drug: KarXT — also filed as BMS-986510
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 3 weeks
Number of participants with adverse events of special interest (AESIs)
measured Up to 3 weeks
Number of participants with serious adverse events (SAEs)
measured Up to 3 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed